GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Debt-to-Equity

Zeo ScientifiX (Zeo ScientifiX) Debt-to-Equity : -0.46 (As of Jan. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Debt-to-Equity?

Zeo ScientifiX's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $673 Mil. Zeo ScientifiX's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $17 Mil. Zeo ScientifiX's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $-1,508 Mil. Zeo ScientifiX's debt to equity for the quarter that ended in Jan. 2024 was -0.46.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Zeo ScientifiX's Debt-to-Equity or its related term are showing as below:

ZEOX' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.98   Med: -0.29   Max: 0.63
Current: -0.46

During the past 13 years, the highest Debt-to-Equity Ratio of Zeo ScientifiX was 0.63. The lowest was -4.98. And the median was -0.29.

ZEOX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs ZEOX: -0.46

Zeo ScientifiX Debt-to-Equity Historical Data

The historical data trend for Zeo ScientifiX's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Debt-to-Equity Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.44 -0.33 -0.31 0.55 -0.56

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 -4.98 -0.78 -0.56 -0.46

Competitive Comparison of Zeo ScientifiX's Debt-to-Equity

For the Biotechnology subindustry, Zeo ScientifiX's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Debt-to-Equity falls into.



Zeo ScientifiX Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Zeo ScientifiX's Debt to Equity Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Zeo ScientifiX's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zeo ScientifiX  (OTCPK:ZEOX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Zeo ScientifiX Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140